154 related articles for article (PubMed ID: 15148627)
21. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
22. Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study.
Paparel P; Chapelon JY; Bissery A; Chesnais S; Curiel L; Gelet A
Prostate Cancer Prostatic Dis; 2008; 11(2):181-6. PubMed ID: 17710106
[TBL] [Abstract][Full Text] [Related]
23. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
[TBL] [Abstract][Full Text] [Related]
24. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
Triozzi PL; Bolger GB; Neidhart J; Rinehart JJ; Saleh M; Allen KO; Sellers S; Waddell MJ
Prostate; 2005 Dec; 65(4):316-21. PubMed ID: 16015596
[TBL] [Abstract][Full Text] [Related]
25. Drug insight: Use of docetaxel in prostate and urothelial cancers.
Mackler NJ; Pienta KJ
Nat Clin Pract Urol; 2005 Feb; 2(2):92-100; quiz 1 p following 112. PubMed ID: 16474654
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel in the treatment of breast cancer: current experience and future prospects.
Nabholtz JM; Gligorov J
Expert Rev Anticancer Ther; 2005 Aug; 5(4):613-33. PubMed ID: 16111463
[TBL] [Abstract][Full Text] [Related]
27. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Protheroe A
Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
[No Abstract] [Full Text] [Related]
28. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
29. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
30. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
31. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
[TBL] [Abstract][Full Text] [Related]
34. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
[TBL] [Abstract][Full Text] [Related]
35. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
37. Severe nail changes due to Docetaxel treatment.
Rafi L; Friedrich M; Tilgen W; Reichrath J
Eur J Dermatol; 2003; 13(6):610-1. PubMed ID: 14721789
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Friedland D; Cohen J; Miller R; Voloshin M; Gluckman R; Lembersky B; Zidar B; Keating M; Reilly N; Dimitt B
Semin Oncol; 1999 Oct; 26(5 Suppl 17):19-23. PubMed ID: 10604264
[TBL] [Abstract][Full Text] [Related]
39. Symptoms in cancer patients and an unusual tumor: Case 2. Docetaxel-related ischemic colitis.
Hussein MA; Bird BR; O'Sullivan MJ; Kalimuthu SG; O'Sullivan GC; O'Reilly S; Breathnach OS
J Clin Oncol; 2005 Dec; 23(36):9424-5. PubMed ID: 16361642
[No Abstract] [Full Text] [Related]
40. New approaches in hormone refractory prostate cancer.
Sonpavde G; Hutson TE
Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]